IL6R and congenital rubella syndrome: Eleven patients (23.4%) had grade 3 cytokine release syndrome (CRS); serum IL-6 levels were significantly elevated in 3 of them post-infusion (greater than 100 times of baseline values), and were treated with IL-6R antagonist tocilizumab.